Lenalidomide Devatis (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to the ubiquitination and degradation of transcription factors such as Ikaros and Aiolos. The resulting actions include anti‑angiogenesis, modulation of immune cell activity, and direct inhibition of malignant cell proliferation.

The specific dose of Lenalidomide Devatis is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Healthcare professionals follow approved labeling and clinical guidelines to select the appropriate strength and dosing schedule for each patient.

Lenalidomide is classified as Pregnancy Category X because it is known to cause fetal harm. It should not be used by pregnant women, and effective contraception is required for both male and female patients of reproductive potential. Breastfeeding is also contraindicated, as the drug can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements if applicable) and the necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens to enhance response rates and may provide oral convenience compared with injectable therapies. Clinical decisions consider efficacy, safety profile, patient comorbidities, and treatment history.

Lenalidomide Devatis should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, controlled environment helps maintain its stability and potency throughout its shelf life.

The medication is taken orally, usually with or without food, as directed by the prescriber. Patients should swallow the tablet whole with a full glass of water and follow the dosing schedule provided in the prescription. Adherence to the prescribed regimen is important for optimal therapeutic effect.

Serious risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, as well as venous thromboembolism, secondary primary malignancies, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for these events, and any signs of serious toxicity should prompt immediate medical evaluation.

Lenalidomide is contraindicated in pregnant women and in individuals who are not using effective contraception if they are of child‑bearing potential. It should also be avoided in patients with known hypersensitivity to lenalidomide or any of its excipients, and in those with uncontrolled severe infections or active thrombotic disease without appropriate prophylaxis.